Instil Bio reports ongoing trials for AXN-2510/IMM2510 in NSCLC; financial results show cash reserves enabling operations beyond 2026. Instil Bio, Inc. announced ongoing enrollment for a clinical ...
Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for its drug AXN-2510 by the FDA, enabling the company to begin a phase 1 trial before the end of 2025. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results